These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34560358)

  • 1. Seizure frequency, quality of life, behavior, cognition, and sleep in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol.
    Anderson CL; Evans V; Gorham L; Liu Z; Johnson CR; Carney PR
    Epilepsy Behav; 2021 Sep; 124():108325. PubMed ID: 34560358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly purified cannabidiol in the treatment of drug-resistant epilepsies: A real-life impact on seizure frequency, quality of life, behavior, and sleep patterns from a single Italian center.
    Ferrera G; Ricci E; Vignoli A; Savini MN; Viganò I; Chiesa V; Caputo D; Zambrelli E; La Briola F; Turner K; Canevini MP
    Epilepsy Behav; 2023 Oct; 147():109409. PubMed ID: 37677907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mediating effects of sleep quality between clinical characteristics and quality of life in children with epilepsy: A cross-sectional study from Southwest China.
    Yan L; Chen J; Xie L; Li T; Hu Y; Hong S; Jiang L
    Epilepsy Behav; 2024 May; 154():109738. PubMed ID: 38513572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy.
    Gaston TE; Ampah SB; Martina Bebin E; Grayson LP; Cutter GR; Hernando K; Szaflarski JP;
    Epilepsy Behav; 2021 Apr; 117():107862. PubMed ID: 33667843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program.
    Park YD; Linder DF; Pope J; Flamini JR; Moretz K; Diamond MP; Long SA
    Epilepsy Behav; 2020 Nov; 112():107474. PubMed ID: 33181893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results.
    Szaflarski JP; Bebin EM; Comi AM; Patel AD; Joshi C; Checketts D; Beal JC; Laux LC; De Boer LM; Wong MH; Lopez M; Devinsky O; Lyons PD; Zentil PP; Wechsler R;
    Epilepsia; 2018 Aug; 59(8):1540-1548. PubMed ID: 29998598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
    Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
    Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol.
    Rosenberg EC; Louik J; Conway E; Devinsky O; Friedman D
    Epilepsia; 2017 Aug; 58(8):e96-e100. PubMed ID: 28617940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
    Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
    Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
    Devinsky O; Marsh E; Friedman D; Thiele E; Laux L; Sullivan J; Miller I; Flamini R; Wilfong A; Filloux F; Wong M; Tilton N; Bruno P; Bluvstein J; Hedlund J; Kamens R; Maclean J; Nangia S; Singhal NS; Wilson CA; Patel A; Cilio MR
    Lancet Neurol; 2016 Mar; 15(3):270-8. PubMed ID: 26724101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.
    Hess EJ; Moody KA; Geffrey AL; Pollack SF; Skirvin LA; Bruno PL; Paolini JL; Thiele EA
    Epilepsia; 2016 Oct; 57(10):1617-1624. PubMed ID: 27696387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term efficacy of cannabidiol in the treatment of refractory epilepsy.
    Patel S; Grinspoon R; Fleming B; Skirvin LA; Wade C; Wolper E; Bruno PL; Thiele EA
    Epilepsia; 2021 Jul; 62(7):1594-1603. PubMed ID: 34050682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy.
    Villanueva V; García-Ron A; Smeyers P; Arias E; Soto V; García-Peñas JJ; González-Alguacil E; Sayas D; Serrano-Castro P; Garces M; Hampel K; Tomás M; Lara J; de Toledo M; Barceló I; Aledo-Serrano A; Gil-Nagel A; Iacampo L; Falip M; Saiz-Diaz RA; Gómez-Ibañez A; Sopelana D; Sanchez-Larsen A; López-González FJ
    Epilepsy Behav; 2022 Dec; 137(Pt A):108958. PubMed ID: 36327646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study.
    Mitelpunkt A; Kramer U; Hausman Kedem M; Zilbershot Fink E; Orbach R; Chernuha V; Fattal-Valevski A; Deutsch L; Heffetz D; Sacks H
    Epilepsy Behav; 2019 Sep; 98(Pt A):233-237. PubMed ID: 31394352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US.
    Sands TT; Rahdari S; Oldham MS; Caminha Nunes E; Tilton N; Cilio MR
    CNS Drugs; 2019 Jan; 33(1):47-60. PubMed ID: 30460546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy.
    Gaston TE; Szaflarski M; Hansen B; Bebin EM; Szaflarski JP;
    Epilepsy Behav; 2019 Jun; 95():10-17. PubMed ID: 31003195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy.
    Kim SH; Choi HS; Koo CM; Joo BR; Park BJ; Lee HK; Lee JS; Kim HD; Kang HC
    J Clin Neurol; 2022 Sep; 18(5):547-552. PubMed ID: 36062772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.
    Devinsky O; Verducci C; Thiele EA; Laux LC; Patel AD; Filloux F; Szaflarski JP; Wilfong A; Clark GD; Park YD; Seltzer LE; Bebin EM; Flamini R; Wechsler RT; Friedman D
    Epilepsy Behav; 2018 Sep; 86():131-137. PubMed ID: 30006259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy.
    Pietrafusa N; Ferretti A; Trivisano M; de Palma L; Calabrese C; Carfì Pavia G; Tondo I; Cappelletti S; Vigevano F; Specchio N
    Paediatr Drugs; 2019 Aug; 21(4):283-290. PubMed ID: 31179531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.